ECCO 2026

IL-23 - is this the good-bye from systemic therapy?

Early treatment concepts with infliximab

Advances in anti‑fibrotic therapy

Update on upadacitinib vs. risankizumab after anti-TNF…

What is the best post-operative strategy in CD?

Fistulizing disease - what can we do better?

IL-23: from real-world to special patient population

Exciting new data on surgery - for all patient groups?

Long-term data on colorectal cancer risk in modern IBD…

Evolving landscape of anti-fibrotic therapy in IBD

Switching to subcutaneous infliximab is safe as a…

Molecular signature–driven therapy

Molecular medicine driving treatment decisioning!?

Stop of thiopurines in patients on subcutaneous…

What is the best treatment approach in IBD?

Top-down- versus Step-up-Therapie beim Morbus Crohn

Was ist der beste Therapieansatz bei CED?

Molekulare Medizin als Wegweiser für…

Should we prevent or treat post-operative recurrence in…

Top-down vs. step-up therapy in CD

Do we need immediate postoperative prophylaxis?

Long-term risankizumab persistence

Early use of infliximab positively influences longterm…

JAK–STAT inhibition as a therapeutic approach for…

Früher Einsatz von Infliximab verbessert das…

LIR!C — suivi 10 ans: bénéfice de la chirurgie?

Is onmiddellijke postoperatieve preventie nodig?

JAK-STAT Hemmung zur Fistel-Therapie

Top-down vs. Step-up Therapie beim Morbus Crohn

Steroid sparing effect of filgotinib in UC

Treat-2-target strategy in UC

ASUC: smarter use of third-line rescue therapy

Pouch surgery: only for expert centers

Long term outcomes after appendicectomy in UC (5 year…

Strategia treat-to-target nella colite ulcerosa

Effetto steroid-sparing di filgotinib nella colite…

Tofacitinib-Steroid-Kombination bei ASUC

Resultados a largo plazo tras apendicectomía en colitis…

Pouchchirurgie: enkel voor expertisecentra

Long-term outcomes of IL‑23 inhibitors

The risk of colorectal neoplasia in IBD

Langetermijn data van IL‑23 inhibitoren

Risque de cancer colorectal dans les MICI

Guselkumab – does it treat only the gut?

Outside the gut - efficacy uf guselkumab in…

UPA vs RISA in Crohn’s disease – a decision dilemma

Histo-endoscopic outcomes of upadacitinib in CD

Guselkumab may improve and prevent extraintestinal…

UPA vs RISA w chorobie Leśniowskiego-Crohna – sztuka…

Guselkumab può migliorare e prevenire le manifestazioni…

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Short-term effectiveness and safety of Mirikizumab in…

Early symptomatic response with IL-23 blockers

Histo-endoscopic outcomes of guselkumab in UC

Etrasimod efficacy in mildly-to-moderately active UC…

Mirikizumab is able to induce disease clearence in…

Etrasimod in the milder moderate UC patients

Does colectomy reduce the risk of death in UC?

Short term transmural healing detected by US in CD…

Vedolizumab combined with upadacitinib vs Vedolizumab…

Efficacy and safety of vedolizumab + upadacitinib as…

Early and durable response with guselkumab

Valutazione a breve termine della guarigione…

Efficacia e sicurezza a lungo termine di risankizumab…

Frühes symptomatisches Ansprechen unter IL-23-Blockade

Efectividad y seguridad a corto plazo de Mirikizumab en…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Est-ce que la colectomie réduit le risque de décès dans…

Efficacia di Etrasimod in pazienti affetti da colite…

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

Appendectomy - a new therapeutic option in UC

Icotrokinra and systemic inflammatory burden in UC

B-cells step into the spotlight

Impact of icotrokinra on biomarkers in UC

Ontunisertib - ALK5 blockage in fistulizing CD

The STENOVA Trial. Ontunisertib shows promising results…

Apendektomie - eine neue Therapieoption bei Colitis…

Ontunisertib – ALK5-Blockade bei fistulierendem Morbus…

Ikotrokinkra a stan zapalny w colitis ulcerosa

AGMB-129, Ontunisertib, nueva terapia para pacientes…

תאי B במרכז העניינים

L’accumulo di cellule citotossiche CD4+ caratterizza la…

Impact de l’icotrokinra sur les biomarqueurs dans la…

ADHD and autism in IBD – the same or different story?

AI endoscopic reads in acute severe UC change the…

IBDMED מעבר לאזור הים התיכון